<DOC>
	<DOCNO>NCT00688545</DOCNO>
	<brief_summary>This multi-center observational Registry collect long-term safety data patient treat celecoxib non-selective nonsteroidal anti-inflammatory drug ( nsNSAIDs ) use clinical practice treatment Juvenile Idiopathic Arthritis ( JIA ) .</brief_summary>
	<brief_title>Naturalistic Safety Registry Of Celecoxib ( CELEBREX ( R ) ) And NSAIDs In Juvenile Idiopathic Arthritis</brief_title>
	<detailed_description>None Study terminate early ( LSLV = 09Jan2012 ) due release postmarketing commitment US FDA . The study stop futility/change treatment paradigm minimize chronic NSAID use safety concern .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Juvenile</mesh_term>
	<mesh_term>Celecoxib</mesh_term>
	<criteria>Age least 2 year less 18 year ; JIA follow subtypes : oligoarthritis , polyarthritis , stable systemic disease ; new treatment ( start 6 month prior ) one NSAID ( celecoxib nsNSAID ) . Patients follow JIA subtypes : active systemic disease , psoriatic Arthritis , enthesitisrelated Arthritis , undifferentiated arthritis ; Patients Reiter 's syndrome ; patient unlikely complete 2 year follow ; Patients need use multiple NSAIDs time .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Celecoxib</keyword>
	<keyword>COX-2</keyword>
	<keyword>NSAIDs</keyword>
	<keyword>observational study</keyword>
	<keyword>noninterventional study</keyword>
	<keyword>cohort study</keyword>
	<keyword>registry</keyword>
	<keyword>epidemiologic study</keyword>
	<keyword>pediatrics</keyword>
	<keyword>rheumatology</keyword>
	<keyword>phase iv study</keyword>
</DOC>